

Claims

10

4 15

20

30

35

- 1. An isolated and/or purified polynucleotide comprising one or more of:
- 5 (a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO: 2;
 - (b) a polynucleotide comprising a nucleotide sequence of SEQ ID NO: 1;
 - (c) a polynucleotide encoding the polypeptide expressed by the DNA contained in NCIMB 41066;
 - (d) a polynucleotide comprising a nucleotide sequence that has at least 70% identity to the polynucleotide of any one of (a) to (c);
 - (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d);
 - (f) a complement to the polynucleotide of any one of (a) to (e); or
 - (g) a polynucleotide fragment of the polynucleotide of any one of (a) to (f).
 - 2. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 75% identity to the polynucleotide of any one of (a) to (c).
 - 3. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 80% identity to the polynucleotide of any one of (a) to (c).
 - 4. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 85% identity to the polynucleotide of any one of (a) to (c).
- The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 90% identity to the polynucleotide of any one of (a) to (c).
 - 6. The polynucleotide of claim 1, comprising a nucleotide sequence that has at least 95% identity to the polynucleotide of any one of (a) to (c).
 - 7. The polynucleotide of claim 1, wherein said polynucleotide encodes a G-protein coupled receptor (GPCR).
 - 8. The polynucleotide of claim 1, wherein said polynucleotide is a probe or primer comprising at least 15 contiguous nucleotides.

A vector comprising a polynucleotide of claim 1.

A host cell transformed or transfected with the vector of claim 9, wherein said host cell expresses the polynucleotide of claim 1 under conditions sufficient for expression of the polynucleotide.

Del 82

11. A process for producing a polypeptide or fragment thereof comprising culturing the transformed/transfected host cell of claim 10 under conditions sufficient for the expression of said polypeptide or fragment.

10

A membrane preparation of a cell of claim 10.

12.

13.

A polypeptide comprising:

15 mg was a man and ma

<u>|-</u>=: (

(1) (2) (1) (1) (2) (3) (1)

- (a) a polypeptide encoded by a polynucleotide of claim 1;
- (b) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 and variants, fragments, homologues, analogues and derivatives thereof;
- (c) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; or
- (d) a polypeptide encoded by the cDNA of NCIMB 41066 and variants, fragments, homologues, analogues and derivatives thereof.
- 14. An antibody against the polypeptide of claim 13.

25

- 15. A compound which modulates the polypeptide of claim 13.
- 16. A pharmaceutical composition comprising the antibody of claim 14 and one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.

30

17. A pharmaceutical composition comprising the compound of claim 15 and one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.

10

15

22.



- 18. A method for identifying a compound which binds to and modulates the polypeptide of claim 13 comprising contacting said polypeptide with a candidate compound and determining whether modulation occurs.
- A method for the treatment of a patient in need thereof comprising administering to the patient a therapeutically effective amount of the antibody of claim 14.
 - 20. A method for the treatment of a patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound of claim 15.
 - 21. The method of claim 20, wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient a polynucleotide sequence encoding said compound, wherein said sequence is expressed in vivo.

An animal cell genetically modified to increase expression of a polynucleotide sequence encoding the polypeptide of claim 13, and/or comprising a functionally disrupted endogenous gene encoding the polypeptide of claim 13.